Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Scientific Reports|February 15, 2018
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)Young Kwang Chae, Sangmin Chang, Taeyeong Ko, et al.JTO Clinical and Research Reports|October 15, 2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 StudyMatthew G Krebs, Martin Forster, Margarita Majem, et al.ERJ Open Research|October 13, 2022
Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitorsEmily Pei-Ying Lin, Li-Ching Huang, Jennifer Whisenant, et al.Academic Medicine : Journal of the Association of American Medical Colleges|March 31, 2016
A Multidisciplinary Housestaff-Led Initiative to Safely Reduce Daily Laboratory TestingWade Iams, Josh Heck, Meghan Kapp, et al.The Oncologist|August 14, 2021
Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer CenterNeha M Jain, Lauren Schmalz, Christopher Cann, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2014
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasHelena A Yu, Camelia S Sima, Ronglai Shen, et al.Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2021
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLCPortia L Thomas, Sarah M Groves, Yun-Kai Zhang, et al.JTO Clinical and Research Reports|September 30, 2021
Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLCJarrod T Smith, Aneri Balar, Dhairya A Lakhani, et al.Pharmacoepidemiology and Drug Safety|November 25, 2024
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung CancerConnor B Grady, Wei-Ting Hwang, Joshua E Reuss, et al.Pageof 3